Vertaling van "atenolol on mortality and " (Frans → Nederlands) :

TERMINOLOGIE

produit contenant de l'aténolol et du bendrofluméthiazide
product dat atenolol en bendroflumethiazide bevat

produit contenant de l'aténolol sous forme parentérale
product dat atenolol in parenterale vorm bevat

produit contenant seulement de l'aténolol et de la nifédipine
product dat enkel atenolol en nifedipine bevat

intoxication par l'aténolol
intoxicatie door atenolol

produit contenant seulement de l'aténolol sous forme orale
product dat enkel atenolol in orale vorm bevat

produit contenant de l'aténolol et de la nifédipine
product dat atenolol en nifedipine bevat

produit contenant de l'aténolol
product dat atenolol bevat

produit contenant de l'aténolol et de la chlortalidone
product dat atenolol en chloortalidon bevat

produit contenant de l'aténolol sous forme orale
product dat atenolol in orale vorm bevat

produit contenant seulement de l'aténolol et de la nifédipine sous forme orale
product dat enkel atenolol en nifedipine in orale vorm bevat

IN-CONTEXT TRANSLATIONS

28. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery.
29. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery.

Aténolol 100 mg: Atenomed, Atenolol-Ratiopharm, Atephar, Docateno, Atenolol BC, Atenolol-Ratiopharm, Atephar, Athenol, Atenotop, Atenolol EG 100, Merck-Atenolol 100, Tenormin 100, Atenolol BC 100, Blokium 100, Kelatenor, etc.
Atenolol 100 mg: Atenomed, Atenolol-Ratiopharm, Atephar, Docateno, Atenolol BC, Atenolol-Ratiopharm, Atephar, Athenol, Atenotop, Atenolol EG 100, Merck-Atenolol 100, Tenormin 100, Atenolol BC 100, Blokium 100, Kelatenor, enz.

- DDD pour produits combinés antihypertenseurs se base sur le nombre le plus plausible d’administrations par jour, nonobstant la teneur des comprimés, par exemple : aténolol-hydrochlorothiazide: 100 mg aténolol + 25 mg hydrochlorothiazide = 1 DDD 50 mg aténolol + 12.5 mg hydrochlorothiazide = 1 DDD 25 mg aténolol + 12,5 mg hydrochlorothiazide = 1 DDD
- DDD voor combinatieproducten antihypertensiva is gebaseerd op het meest waarschijnlijke aantal toedieningen per dag onafhankelijk van de zwaarte van de tabletten. vb : 100 mg. atenolol – 25 mg. hydrochloorthiazide = 1 DDD 50 mg. atenolol - 12,5 mg. hydrochloorthiazide = 1 DDD 25 mg. atenolol - 12,5 mg. hydrochloorthiazide = 1 DDD

C02 ANTIHYPERTENSEURS 14.859.953 16.724.592 17.937.410 19.088.272 20.756.876 22.542.010 23.692.402 24.247.299 25.983.268 C03 DIURETIQUES 148.621.272 156.784.675 157.907.473 161.135.875 166.908.927 168.016.365 170.625.823 172.378.222 182.418.333 C07 sauf Atenolol BETA-BLOQUANTS SAUF ATENOLOL 161.787.248 171.919.864 178.846.755 187.969.148 200.249.462 207.361.006 217.995.910 229.899.101 250.521.536 C07AB03 + C07CB03 + C07FB03 + C07DB01 ATENOLOL, SIMPLE ET COMBINAISONS 57.861.718 58.836.176 56.929.382 55.201.549 53.870.746 50.878.954 48.517.938 45.684.078 44.878.780 C08 sauf C08CA ANTAG.
C02 ANTIHYPERTENSIVA 14.859.953 16.724.592 17.937.410 19.088.272 20.756.876 22.542.010 23.692.402 24.247.299 25.983.268 C03 DIURETICA 148.621.272 156.784.675 157.907.473 161.135.875 166.908.927 168.016.365 170.625.823 172.378.222 182.418.333 C07 uitgezonderd Atenolol BETA-BLOKKERS ZONDER ATENOLOL 161.787.248 171.919.864 178.846.755 187.969.148 200.249.462 207.361.006 217.995.910 229.899.101 250.521.536 C07AB03 + C07CB03 + C07FB03 + C07DB01 ATENOLOL, ENKELVOUDIG EN GECOMBINEERD 57.861.718 58.836.176 56.929.382 55.201.549 53.870.746 50.878.954 48.517.938 45.684.078 44.878.780 C08 uitgezonderd C08CA CALCIUMANTAG.

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

To asses the effects of poorer outcomes, we added the peri-procedural mortality of low volume centres in the US, using the observed risk ratio of death to the risks of stroke or death; low volume centres showed a 1.8 times higher peri-procedural mortality. 50
To asses the effects of poorer outcomes, we added the peri-procedural mortality of low volume centres in the US, using the observed risk ratio of death to the risks of stroke or death; low volume centres showed a 1.8 times higher peri-procedural mortality.[50]

The graphs „Medical treatment‰ and „trial centres‰ show the results of the ACST/ACAS trials (expressed as constant hazards of stroke or death from the trials and age dependent hazards of all other cause mortality from the Flemish male life table at age 70 in the year 2000). 18 Intervention starts with a short period of high (peri-procedural) mortality, but the lower post-procedural hazard of death will overtake the higher hazard of medical treatment.
The graphs „Medical treatment‰ and „trial centres‰ show the results of the ACST/ACAS trials (expressed as constant hazards of stroke or death from the trials and age dependent hazards of all other cause mortality from the Flemish male life table at age 70 in the year 2000).[18] Intervention starts with a short period of high (peri-procedural) mortality, but the lower post-procedural hazard of death will overtake the higher hazard of medical treatment.

„Atenolol Tenormin 0,5 mg – 5 mg/kg/jour PO‰.
„Atenolol Tenormin 0,5 mg – 5mg/kg/dag PO‰.

Brusselaers N, Monstrey S, Vogelaers D, Hoste E, Blot S. Severe burn injury in Europe: a systematic review of the incidence, etiology, morbidity, and mortality.
12. Jennes S, Casaer, M., Colpaert, K., Magnette, A. Aanbevelingen van de BABI: Pre- en intrahospitaal management van zwaar verbranden buiten een brandwondencentrum tijdens de eerste 72 uren na de verbranding. In: Belgian Association for Burn Injuries; 2007.

FA + iron (60 mg), FA + iron + or without zinc (30 mg), or multiple iron) or micronutrients (MNs; the iron + zinc foregoing plus 10 microg vitamin had a D, 10 mg vitamin E, 1.6 mg consistent thiamine, 1.8 mg riboflavin, 2.2 mg pattern of vitamin B-6, 2.6 microg vitamin B- 15-20% 12, 100 mg vitamin C, 64 microg lower 3-mo vitamin K, 20 mg niacin, 2 mg Cu, mortality; and 100 mg Mg).
zinc (30 mg), or multiple iron) or micronutrients (MNs; the iron + zinc foregoing plus 10 microg vitamin had a D, 10 mg vitamin E, 1.6 mg consistent thiamine, 1.8 mg riboflavin, 2.2 mg pattern of vitamin B-6, 2.6 microg vitamin B- 15-20% 12, 100 mg vitamin C, 64 microg lower 3-mo vitamin K, 20 mg niacin, 2 mg Cu, mortality; and 100 mg Mg).